全文获取类型
收费全文 | 2915篇 |
免费 | 189篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 38篇 |
儿科学 | 67篇 |
妇产科学 | 55篇 |
基础医学 | 539篇 |
口腔科学 | 46篇 |
临床医学 | 249篇 |
内科学 | 463篇 |
皮肤病学 | 70篇 |
神经病学 | 385篇 |
特种医学 | 102篇 |
外国民族医学 | 4篇 |
外科学 | 280篇 |
综合类 | 8篇 |
一般理论 | 2篇 |
预防医学 | 288篇 |
眼科学 | 43篇 |
药学 | 240篇 |
中国医学 | 12篇 |
肿瘤学 | 219篇 |
出版年
2023年 | 36篇 |
2022年 | 57篇 |
2021年 | 95篇 |
2020年 | 50篇 |
2019年 | 78篇 |
2018年 | 97篇 |
2017年 | 73篇 |
2016年 | 93篇 |
2015年 | 85篇 |
2014年 | 114篇 |
2013年 | 128篇 |
2012年 | 238篇 |
2011年 | 240篇 |
2010年 | 155篇 |
2009年 | 116篇 |
2008年 | 232篇 |
2007年 | 191篇 |
2006年 | 161篇 |
2005年 | 150篇 |
2004年 | 162篇 |
2003年 | 168篇 |
2002年 | 95篇 |
2001年 | 14篇 |
2000年 | 20篇 |
1999年 | 26篇 |
1998年 | 33篇 |
1997年 | 32篇 |
1996年 | 15篇 |
1995年 | 9篇 |
1994年 | 15篇 |
1993年 | 4篇 |
1992年 | 10篇 |
1991年 | 8篇 |
1990年 | 12篇 |
1989年 | 6篇 |
1988年 | 10篇 |
1987年 | 9篇 |
1986年 | 11篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1979年 | 7篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1973年 | 5篇 |
1972年 | 5篇 |
1971年 | 8篇 |
1970年 | 4篇 |
1969年 | 3篇 |
1966年 | 3篇 |
排序方式: 共有3110条查询结果,搜索用时 31 毫秒
21.
22.
Hao Wang Ingeborg Barisic Maria Loane Marie‐Claude Addor Linda M. Bailey Miriam Gatt Kari Klungsoyr Olatz Mokoroa Vera Nelen Amanda J. Neville Mary O'Mahony Anna Pierini Anke Rissmann Christine Verellen‐Dumoulin Hermien E.K. de Walle Awi Wiesel Katarzyna Wisniewska Lolkje T.W. de Jong‐van den Berg Helen Dolk Babak Khoshnood Ester Garne 《American journal of medical genetics. Part A》2019,179(4):595-601
We aimed to assess prevalence, birth outcome, associated anomalies and prenatal diagnosis of congenital clubfoot in Europe using data from the EUROCAT network, and to validate the recording of congenital clubfoot as a major congenital anomaly by EUROCAT registries. Cases of congenital clubfoot were included from 18 EUROCAT registries covering more than 4.8 million births in 1995–2011. Cases without chromosomal anomalies born during 2005–2009, were randomly selected for validation using a questionnaire on diagnostic details and treatment. There was 5,458 congenital clubfoot cases of which 5,056 (93%) were liveborn infants. Total prevalence of congenital clubfoot was 1.13 per 1,000 births (95% CI 1.10–1.16). Prevalence of congenital clubfoot without chromosomal anomaly was 1.08 per 1,000 births (95% CI 1.05–1.11) and prevalence of isolated congenital clubfoot was 0.92 per 1,000 births (95% CI 0.90–0.95), both with decreasing trends over time and large variations in prevalence by registry. The majority of cases were isolated congenital clubfoot (82%) and 11% had associated major congenital anomalies. Prenatal detection rate of isolated congenital clubfoot was 22% and increased over time. Among 301 validated congenital clubfoot cases, diagnosis was confirmed for 286 (95%). In conclusion, this large population‐based study found a decreasing trend of congenital clubfoot in Europe after 1999–2002, an increasing prenatal detection rate, and a high standard of coding of congenital clubfoot in EUROCAT. 相似文献
23.
Timo D Müller Anke Hinney André Scherag Thuy T Nguyen Felix Schreiner Helmut Schäfer Johannes Hebebrand Christian L Roth Thomas Reinehr 《BMC medical genetics》2008,9(1):85
Background
We have previously identified strong association of six single nucleotide polymorphisms (SNPs) in FTO (fat mass and obesity associated gene) to early onset extreme obesity within the first genome wide association study (GWA) for this phenotype. The aim of this study was to investigate whether the obesity risk allele of one of these SNPs (rs9939609) is associated with weight loss in a lifestyle intervention program. Additionally, we tested for association of rs9939609 alleles with fasting blood parameters indicative of glucose and lipid metabolism. 相似文献24.
Ribasés M Gratacòs M Fernández-Aranda F Bellodi L Boni C Anderluh M Cavallini MC Cellini E Di Bella D Erzegovesi S Foulon C Gabrovsek M Gorwood P Hebebrand J Hinney A Holliday J Hu X Karwautz A Kipman A Komel R Nacmias B Remschmidt H Ricca V Sorbi S Wagner G Treasure J Collier DA Estivill X 《Human molecular genetics》2004,13(12):1205-1212
Several genes with an essential role in the regulation of eating behavior and body weight are considered candidates involved in the etiology of eating disorders (ED), but no relevant susceptibility genes with a major effect on anorexia nervosa (AN) or bulimia nervosa (BN) have been identified. Brain-derived neurotrophic factor (BDNF) has been implicated in the regulation of food intake and body weight in rodents. We previously reported a strong association of the Met66 allele of the Val66Met BDNF variant with restricting AN (ANR) and low minimum body mass index in Spanish patients. Another single nucleotide polymorphism located in the promoter region of the BDNF gene (-270C>T) showed lack of association with any ED phenotype. In order to replicate these findings in a larger sample, we performed a case-control study in 1142 Caucasian patients with ED consecutively recruited in six different centers from five European countries (France, Germany, Italy, Spain and UK) participating in the 'Factors in Healthy Eating' project. We have found that the Met66 variant is strongly associated to all ED subtypes (AN, ANR, binge-eating/purging AN and BN), and that the -270C BDNF variant has an effect on BN and late age at onset of weight loss. These are the first two variants associated with the pathophysiology of ED in different populations and support a role for BDNF in the susceptibility to aberrant eating behaviors. 相似文献
25.
Krausse-Opatz B Schmidt C Fendrich U Bialowons A Kaever V Zeidler H Kuipers J Köhler L 《Microbial pathogenesis》2004,37(3):155-161
Chlamydia trachomatis (CT) as well as Chlamydophila pneumoniae (CP) cause chronic inflammatory diseases in humans. Persistently infected monocytes are involved in the pathogenesis by inducing mediators of inflammation. An in vitro system of chlamydial persistence in human peripheral blood monocytes (HPBM) was used to investigate prostaglandin E(2) (PGE(2)) production and the expression of the key enzyme for prostaglandin production, cyclooxygenase-2 (COX-2). PGE(2) production was determined by PGE(2)-ELISA of HPBM-culture supernatants. Cox-2 mRNA expression was measured by real-time RT-PCR of total RNA isolated from HPBM. Both, CT and CP, stimulated PGE(2) production of HPBM in vitro. Equivalent numbers of CT per host cell induced a higher PGE(2)-response compared to CP. The amount of synthesized PGE(2) depended on the chlamydial multiplicity of infection (MOI). Even at an MOI of 10 the amount of CT- and CP-induced prostaglandin, respectively, was lower than the amount of prostaglandin induced by E. coli lipopolysaccharide (LPS) at a concentration of 10microg/ml. In contrast to stimulation with LPS, Chlamydia-induced PGE(2) production as well as cox-2 mRNA decreased after day 1 post infection (p.i.). These data indicate that Chlamydia stimulate PGE(2) production in human monocytes. Since Chlamydia are often contaminated by mycoplasma, the influence of mycoplasma on the prostaglandin production was investigated additionally. Mycoplasma fermentans (MF) also stimulated PGE(2) production. The co-infection of mycoplasma and Chlamydia resulted in an additive effect in the production of PGE(2). Thus it is important to use host cells and Chlamydia free of mycoplasma contamination for the analysis of Chlamydia-induced prostaglandin production. 相似文献
26.
Renske M.T. ten Ham Merel van Nuland Rick A. Vreman Laurens G. de Graaf Hilde Rosing André M. Bergman Alwin D.R. Huitema Jos H. Beijnen Anke M. Hövels 《Value in health》2021,24(1):121-128
ObjectivesAbiraterone acetate is registered for the treatment of metastatic castration-sensitive and resistant prostate cancer (mCRPC). Treatment outcome is associated with plasma trough concentrations (Cmin) of abiraterone. Patients with a plasma Cmin below the target of 8.4 ng/mL may benefit from treatment optimization by dose increase or concomitant intake with food. This study aims to investigate the cost-effectiveness of monitoring abiraterone Cmin in patients with mCRPC.MethodsA Markov model was built with health states progression-free survival, progressed disease, and death. The benefits of monitoring abiraterone Cmin followed by a dose increase or food intervention were modeled via a difference in the percentage of patients achieving adequate Cmin taking a healthcare payer perspective. Deterministic and probabilistic sensitivity analyses were performed to assess uncertainties and their impac to the incremental cost-effectiveness ratio (ICER).ResultsMonitoring abiraterone followed by a dose increase resulted in 0.149 incremental quality-adjusted life-years (QALYs) with €22 145 incremental costs and an ICER of €177 821/QALY. The food intervention assumed equal effects and estimated incremental costs of €7599, resulting in an ICER of €61 019/QALY. The likelihoods of therapeutic drug monitoring (TDM) with a dose increase or food intervention being cost-effective were 8.04%and 81.9%, respectively.ConclusionsMonitoring abiraterone followed by a dose increase is not cost-effective in patients with mCRPC from a healthcare payer perspective. Monitoring in combination with a food intervention is likely to be cost-effective. This cost-effectiveness assessment may assist decision making in future integration of abiraterone TDM followed by a food intervention into standard abiraterone acetate treatment practices of mCRPC patients. 相似文献
27.
Spura Anke Reibling Nadine Thaiss Heidrun M. De Bock Freia 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2021,64(12):1481-1482
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - 相似文献
28.
Gretl Hendrickx Verena Fischer Astrid Liedert Simon von Kroge Melanie Haffner-Luntzer Laura Brylka Eva Pawlus Michaela Schweizer Timur Yorgan Anke Baranowsky Tim Rolvien Mona Neven Udo Schumacher David J Beech Michael Amling Anita Ignatius Thorsten Schinke 《Journal of bone and mineral research》2021,36(2):369-384
29.
30.
Wenjie Bi Anke Kraft Sophie Engelskircher Jasmin Mischke Moana Witte Frank Klawonn Marco van Ham Markus Cornberg Heiner Wedemeyer Julia Hengst Lothar Jänsch 《European journal of immunology》2023,53(11):2250291
Chronic hepatitis C virus (HCV) infections compromise natural killer (NK)-cell immunity. Direct-acting antivirals (DAA) effectively eliminate HCV, but the long-term effects on NK cells in cured patients are debated. We conducted a proteomic study on CD56+ NK cells of chronic HCV-infected patients before and 1 year after DAA therapy. Donor-variation was observed in NK-cell proteomes of HCV-infected patients, with 46 dysregulated proteins restored after DAA therapy. However, 30% of the CD56+ NK-cell proteome remained altered 1 year post-therapy, indicating a phenotypic shift with low donor-variation. NK cells from virus-negative cured patients exhibited global regulation of RNA-processing and pathways related to “stimuli response”, “chemokine signaling”, and “cytotoxicity regulation”. Proteomics identified downregulation of vesicle transport components (CD107a, COPI/II complexes) and altered receptor expression profiles, indicating an inhibited NK-cell phenotype. Yet, activated NK cells from HCV patients before and after therapy effectively upregulated IFN-γ and recruited CD107a. Conversely, reduced surface expression levels of Tim-3 and 2B4 were observed before and after therapy. In conclusion, this study reveals long-term effects on the CD56+ NK-cell compartment in convalescent HCV patients 1 year after therapy, with limited abundance of vesicle transport complexes and surface receptors, associated with a responsive NK-cell phenotype. 相似文献